Pharma/Payer Deals: 2011 Saw Important Step In Shift To Value-based R&D
Three major drug makers inked broad alliances with the research departments of major US payers in 2011. The alliances signal that even as pharma reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.
You may also be interested in...
With the development of targeted therapies and companion diagnostics increasing, AmerisourceBergen Consulting’s president advises pharma industry to bring payers in around Phase II to ensure trials give them data they need to cover drugs and diagnostics.
New Insurance Marketplaces Won’t ‘Move The Needle’ Near-Term For Pharma Economics – An Interview With Booz & Co.
Jan. 1, 2014, the date insurance coverage expansion begins, is a key marker in the implementation of the Affordable Care Act, but experts, including Booz & Co. partners Elizabeth Powers and Greg Rotz say it isn’t likely to have a big near-term impact on drug manufacturers. Initial enrollment into health insurance exchanges and expanded Medicaid programs is expected to be limited, benefit plan designs are still unknown, and many uncertainties remain.
Driving Rx Adherence In Value-Based Insurance Design Needs More Than Lower Copays – Harvard Researcher
Value-based insurance design offers the promise of offering better quality care and helping to reduce costs, but getting there will require more than trying to influence behavior by reducing copayments, Harvard’s Choudhry said in a recent webinar.